SCHEMBL1603363

SCHEMBL1603363

O=C(CN1CCc2nc(NC3CCCCC3)ccc2C1)N1CCN(C2CCC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 4/20 0.40
PARP1 P09874 1/20 0.40
SIGMAR1 Q99720 1/20 0.38
POLB P06746 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HRH3 Q9Y5N1 5/20 0.38
KCNH2 Q12809 1/20 0.38
LRRK2 Q5S007 1/20 0.38
CDK4 P11802 2/20 0.38
FLT3 P36888 1/20 0.38
CDK2 P24941 1/20 0.38
CDK6 Q00534 1/20 0.38
NAMPT P43490 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 1/20 0.37
ENPP2 Q13822 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019682 0.99 PARP1 (0.40) ALDH1A1KDM4EPARP1SIGMAR1POLB
SCHEMBL1016832 0.98 PARP1 (0.39) ALDH1A1KDM4EPARP1SIGMAR1HSD17B10
SCHEMBL1020144 0.88 NPY5R (0.38) ALDH1A1KDM4EPARP1HSD17B10HRH3
SCHEMBL1016650 0.86 NPY5R (0.38) ALDH1A1KDM4EPARP1HSD17B10HRH3
SCHEMBL12953864 0.86 PARP1 (0.37) ALDH1A1KDM4EPARP1HSD17B10HRH3
SCHEMBL1018540 0.84 CDK4 (0.37) ALDH1A1KDM4EPARP1HSD17B10HRH3
SCHEMBL1018763 0.84 ADRA1A (0.38) ALDH1A1KDM4EPARP1HRH3KCNH2
SCHEMBL1017991 0.84 CDK4 (0.36) ALDH1A1KDM4EPARP1HRH3KCNH2
SCHEMBL1016696 0.84 CDK4 (0.36) ALDH1A1KDM4EPARP1HRH3KCNH2
SCHEMBL1018392 0.84 PDCD1 (0.39) ALDH1A1KDM4EPARP1SIGMAR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
WO-2007106349-A2 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 ALDH1A1 1229/4885KDM4E 2634/4885PARP1 3633/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ALDH1A1 1229/4885KDM4E 2634/4885PARP1 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.